| 2024-10-30 | +9.9% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2023-04-27 | -9.5% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2025-01-31 | +9.5% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2025-10-31 | -7.6% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2025-10-31 | -7.6% | news | Yahoo Finance | Why AbbVie (ABBV) Shares Are Falling Today - Yahoo Finance |
| 2022-07-29 | -7.5% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2025-05-13 | -7.4% | legal | SEC EDGAR | ABBV 8-K: 5.02 and 5.07 (SEC Filing) |
| 2022-10-28 | -6.3% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2023-07-27 | +6.0% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2024-04-03 | -6.0% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2025-04-25 | +5.9% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2023-02-09 | +5.8% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2025-07-31 | +5.1% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2026-03-17 | -4.8% | news | Yahoo Finance | AbbVie Inc. (ABBV): Billionaire Ken Fisher Admires This Pharma Stock - Yahoo Finance |
| 2026-03-17 | -4.8% | news | Yahoo Finance | AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock? - Yahoo Finance |
| 2025-11-12 | +4.8% | earnings | Yahoo Finance | AbbVie (ABBV) Surged Following Strong Results and Increased Guidance - Yahoo Finance |
| 2024-04-26 | -4.8% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2026-03-18 | -4.5% | news | Seeking Alpha | J&Js new psoriasis pill to rival AbbVies Skyrizi: BNP Paribas |
| 2026-03-18 | -4.5% | earnings | TIKR.com | AbbVie Stock: EPS Set to Jump 45% in 2026 as Skyrizi and Rinvoq Dominate IBD - TIKR.com |
| 2026-03-18 | -4.5% | news | Benzinga | What's Going On With AbbVie Stock Today? - AbbVie (NYSE:ABBV) - Benzinga |
| 2026-03-18 | -4.5% | news | Quiver Quantitative | AbbVie (ABBV) slides as investors weigh policy-related pricing risk and recent financing activity - Quiver Quantitative |
| 2026-03-18 | -4.5% | news | MarketWatch | AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch |
| 2024-07-25 | +4.5% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2025-10-02 | -4.4% | analyst | Yahoo Finance | Leerink Raises AbbVie (ABBV) Price Target on Strong Business Performance - Yahoo Finance |
| 2021-10-29 | +4.3% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2022-02-02 | +4.1% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2026-02-18 | -3.9% | earnings | Yahoo Finance | Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited - Yahoo Finance |
| 2021-04-30 | +3.9% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2026-04-10 | -3.7% | news | Seeking Alpha | Dividend Roundup: AGNC Investments, Abbott Labs, AbbVie, and more |
| 2026-04-10 | -3.7% | news | Seeking Alpha | AbbVie: Fairly Valued And Positioned For Growth |
| 2026-04-10 | -3.7% | news | TradingView | Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer? - TradingView |
| 2026-01-05 | -3.6% | news | Yahoo Finance | AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance |
| 2026-01-15 | -3.6% | news | Yahoo Finance | AbbVie (ABBV) Stock Dips While Market Gains: Key Facts - Yahoo Finance |
| 2023-01-06 | -3.4% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2026-02-26 | +3.3% | earnings | Seeking Alpha | Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie |
| 2026-02-26 | +3.3% | legal | SEC EDGAR | ABBV 8-K: 8.01 and (SEC Filing) |
| 2022-04-21 | +3.1% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2022-03-04 | +3.1% | legal | SEC EDGAR | ABBV 8-K: 5.02 (SEC Filing) |
| 2022-07-06 | -3.1% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2025-10-03 | -3.0% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2023-10-27 | -3.0% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2026-03-27 | +3.0% | news | Seeking Alpha | AbbVie: Strong 2026 Outlook, Expect Dividend Increases |
| 2022-04-13 | -2.9% | legal | SEC EDGAR | ABBV 8-K: 5.02 (SEC Filing) |
| 2026-03-31 | -2.8% | news | Seeking Alpha | Trump tax cuts deliver $65B in savings for big businesses: report |
| 2022-06-28 | +2.8% | legal | SEC EDGAR | ABBV 8-K: 5.02 (SEC Filing) |
| 2026-04-22 | -2.7% | news | Seeking Alpha | AbbVie announces new $1.4B manufacturing campus in North Carolina |
| 2026-04-22 | -2.7% | news | MEXC | AbbVie (ABBV) Stock Jumps On $1.4 Billion North Carolina Campus Announcement - MEXC |
| 2026-04-22 | -2.7% | news | MSN | AbbVie Inc. (ABBV) is attracting investor attention: Here is what you should know - MSN |
| 2026-04-22 | -2.7% | expansion | Yahoo Finance | AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development - Yahoo Finance |
| 2026-04-22 | -2.7% | earnings | MarketBeat | Kingswood Wealth Advisors LLC Raises Stock Holdings in AbbVie Inc. $ABBV - MarketBeat |
| 2026-04-22 | -2.7% | earnings | MarketBeat | KLP Kapitalforvaltning AS Buys 29,600 Shares of AbbVie Inc. $ABBV - MarketBeat |
| 2026-04-22 | -2.7% | earnings | MarketBeat | AbbVie Inc. $ABBV Position Lowered by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat |
| 2026-04-22 | -2.7% | earnings | MarketBeat | Clarity Financial LLC Sells 23,870 Shares of AbbVie Inc. $ABBV - MarketBeat |
| 2026-04-22 | -2.7% | earnings | MarketBeat | TABR Capital Management LLC Purchases Shares of 47,486 AbbVie Inc. $ABBV - MarketBeat |
| 2026-04-22 | -2.7% | news | Stock Titan | 734 jobs, 185 acres: AbbVie picks Durham for $1.4B drug hub - Stock Titan |
| 2026-04-22 | -2.7% | earnings | MarketBeat | M&T Bank Corp Lowers Holdings in AbbVie Inc. $ABBV - MarketBeat |
| 2026-04-22 | -2.7% | earnings | MarketBeat | FORM Wealth Advisors LLC Takes $1.97 Million Position in AbbVie Inc. $ABBV - MarketBeat |
| 2026-04-22 | -2.7% | news | Seeking Alpha | AbbVie announces new $1.4B manufacturing campus in North Carolina - Seeking Alpha |
| 2026-04-22 | -2.7% | earnings | MarketBeat | AbbVie Inc. $ABBV Shares Bought by Migdal Insurance & Financial Holdings Ltd. - MarketBeat |
| 2026-04-22 | -2.7% | earnings | Cổng thông tin điện tử Tỉnh Sơn La | ABBV (AbbVie Inc.) edges past Q4 2025 EPS estimates, posts 8.6 percent revenue growth, shares dip 0.88 percent. - Social Trading Insights - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-04-22 | -2.7% | news | GuruFocus | HANCOCK WHITNEY CORP's AbbVie Inc(ABBV) Holding History - GuruFocus |
| 2026-04-22 | -2.7% | earnings | Cổng thông tin điện tử tỉnh Lào Cai | ABBV (AbbVie Inc.) edges past Q4 2025 EPS estimates, posts 8.6 percent revenue growth, shares dip 0.88 percent. - Cổng thông tin điện tử tỉnh Lào Cai |
| 2022-10-17 | -2.6% | legal | SEC EDGAR | ABBV 8-K: 5.02 and (SEC Filing) |
| 2026-02-20 | +2.6% | legal | Seeking Alpha | AbbVie wins FDA nod for Venclexta-acalabrutinib combo in first-line chronic lymphocytic leukemia |
| 2026-02-20 | +2.6% | news | Seeking Alpha | Dividend Roundup: Halliburton, AbbVie, Johnson & Johnson, Delta Air Lines, and more |
| 2025-02-19 | +2.5% | legal | SEC EDGAR | ABBV 8-K: 8.01 and (SEC Filing) |
| 2026-02-03 | -2.5% | news | Yahoo Finance | What Does Wall Street Think About AbbVie Inc. (ABBV)? - Yahoo Finance |
| 2022-04-29 | -2.3% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2026-04-09 | -2.2% | earnings | Seeking Alpha | AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It's A Buy, But With Caveats (Upgrade) |
| 2026-04-09 | -2.2% | news | Seeking Alpha | AbbVie: Fairly Valued And Positioned For Growth (NYSE:ABBV) - Seeking Alpha |
| 2026-04-09 | -2.2% | earnings | Seeking Alpha | AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It's A Buy, But With Caveats (Upgrade) (ABBV) - Seeking Alpha |
| 2025-11-05 | +2.2% | news | Yahoo Finance | AbbVie Just Raised Its Dividend by 5.5%. Should You Buy ABBV Stock Here? - Yahoo Finance |
| 2021-07-30 | -2.2% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2026-02-19 | -2.2% | M&A | Seeking Alpha | China drug licensing deals surge nearly 10-fold in value since 2021 |
| 2026-02-13 | +2.1% | news | Yahoo Finance | Where is AbbVie Inc. (ABBV) Headed According to the Street? - Yahoo Finance |
| 2026-03-09 | -2.1% | news | Seeking Alpha | Top 10 healthcare stocks with highest dividend yield amid volatile markets |
| 2026-03-09 | -2.1% | news | Seeking Alpha | AbbVie sees promising early-stage data for weight loss asset ABBV-295 |
| 2026-03-09 | -2.1% | earnings | Seeking Alpha | FDA issues draft guidance to relax testing rules to encourage biosimilar drugs |
| 2026-03-09 | -2.1% | news | Yahoo Finance | AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease - Yahoo Finance |
| 2026-04-19 | -2.0% | earnings | MarketBeat | AbbVie Inc. $ABBV Shares Sold by Berger Financial Group Inc - MarketBeat |
| 2024-10-03 | -2.0% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2025-02-26 | +2.0% | legal | SEC EDGAR | ABBV 8-K: 8.01 and (SEC Filing) |
| 2026-04-21 | -1.9% | earnings | MarketBeat | SageGuard Financial Group LLC Purchases New Shares in AbbVie Inc. $ABBV - MarketBeat |
| 2026-04-21 | -1.9% | earnings | MarketBeat | Private Wealth Partners LLC Sells 6,413 Shares of AbbVie Inc. $ABBV - MarketBeat |
| 2026-04-21 | -1.9% | earnings | MarketBeat | TD Waterhouse Canada Inc. Lowers Position in AbbVie Inc. $ABBV - MarketBeat |
| 2026-04-21 | -1.9% | earnings | MarketBeat | DSG Capital Advisors LLC Buys 5,090 Shares of AbbVie Inc. $ABBV - MarketBeat |
| 2026-02-25 | -1.9% | analyst | Seeking Alpha | AbbVie a new outperform at RBC Capital Markets on durable growth |
| 2026-02-23 | +1.9% | news | Seeking Alpha | AbbVie earmarks $380M to build two manufacturing facilities in Illinois |
| 2026-02-23 | +1.9% | analyst | Yahoo Finance | Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential - Yahoo Finance |
| 2024-05-08 | -1.9% | legal | SEC EDGAR | ABBV 8-K: 5.02 and 5.07 (SEC Filing) |
| 2021-12-17 | +1.8% | legal | SEC EDGAR | ABBV 8-K: 5.02 (SEC Filing) |
| 2021-12-16 | +1.7% | legal | SEC EDGAR | ABBV 8-K: 5.02 (SEC Filing) |
| 2025-10-01 | +1.7% | news | Yahoo Finance | Why AbbVie (ABBV) Stock Is Trading Up Today - Yahoo Finance |
| 2026-04-06 | -1.7% | earnings | Seeking Alpha | AbbVie: A High 2026 Earnings Bar, But Shares Are Attractive On Valuation |
| 2026-04-06 | -1.7% | earnings | Seeking Alpha | AbbVie lowers Q1 and FY 2026 earnings outlook following $744M R&D charge |
| 2026-04-06 | -1.7% | news | Yahoo Finance | AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance |
| 2026-04-06 | -1.7% | earnings | MarketBeat | AbbVie (NYSE:ABBV) Stock Price Down 1.1% - Time to Sell? - MarketBeat |
| 2026-04-06 | -1.7% | earnings | Seeking Alpha | AbbVie: A High 2026 Earnings Bar, But Shares Are Attractive On Valuation (NYSE:ABBV) - Seeking Alpha |
| 2026-04-11 | -1.7% | earnings | MarketBeat | Factory Mutual Insurance Co. Decreases Stock Position in AbbVie Inc. $ABBV - MarketBeat |
| 2025-07-03 | -1.7% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2026-03-06 | -1.7% | M&A | Seeking Alpha | Pharma giants pressed by Senate Democrats over Trump pricing deals |
| 2026-04-15 | -1.6% | analyst | Yahoo Finance | Evercore ISI Tweaks AbbVie (ABBV) Estimates, Lowers Price Target Marginally - Yahoo Finance |
| 2025-04-03 | +1.6% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2026-03-02 | +1.6% | news | Seeking Alpha | AbbVie sees positive late-stage results for subcutaneous Skyrizi in Crohn's |
| 2024-01-05 | -1.6% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2026-02-02 | +1.5% | news | Yahoo Finance | AbbVie Inc. (ABBV): A Bull Case Theory - Yahoo Finance |
| 2026-01-13 | +1.5% | news | Yahoo Finance | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance |
| 2025-12-03 | +1.5% | news | Yahoo Finance | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance |
| 2024-02-02 | +1.5% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2026-04-03 | -1.5% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2026-04-03 | -1.5% | earnings | Stock Titan | AbbVie (NYSE: ABBV) trims 2026 EPS guidance after $744M IPR&D expense - Stock Titan |
| 2025-09-08 | -1.5% | news | Yahoo Finance | AbbVie (ABBV) Stock Dips While Market Gains: Key Facts - Yahoo Finance |
| 2026-04-16 | -1.5% | earnings | MarketBeat | Adelphi Trust Co Makes New Investment in AbbVie Inc. $ABBV - MarketBeat |
| 2026-04-16 | -1.5% | earnings | MarketBeat | Diversified Management Inc. Takes Position in AbbVie Inc. $ABBV - MarketBeat |
| 2026-04-16 | -1.5% | earnings | MarketBeat | Lbp Am Sa Purchases 8,678 Shares of AbbVie Inc. $ABBV - MarketBeat |
| 2026-03-12 | -1.4% | news | Yahoo Finance | RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages - Yahoo Finance |
| 2025-10-22 | -1.4% | analyst | Yahoo Finance | Analyst Says He Likes AbbVie (ABBV) Amid ‘Attractive’ Valuation - Yahoo Finance |
| 2024-12-13 | -1.3% | legal | SEC EDGAR | ABBV 8-K: 5.02 (SEC Filing) |
| 2026-03-30 | +1.3% | earnings | MarketBeat | AbbVie (NYSE:ABBV) Stock Price Up 1.8% - Should You Buy? - MarketBeat |
| 2026-04-23 | -1.3% | legal | MT Newswires | AbbVie Gets FDA Complete Response Letter on TrenibotE BLA |
| 2026-04-23 | -1.3% | earnings | StockStory | Spotting Winners: AbbVie (NYSE:ABBV) And Therapeutics Stocks In Q4 |
| 2026-04-23 | -1.3% | news | PR Newswire | AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S. |
| 2026-04-23 | -1.3% | news | Yahoo Finance | AbbVie (ABBV): The Best Stock to Buy on a Pullback - Yahoo Finance |
| 2026-04-23 | -1.3% | news | ChartMill | ABBV Technical Analysis | Trend, Signals & Chart Patterns | ABBVIE INC (NYSE:ABBV) - ChartMill |
| 2026-04-23 | -1.3% | earnings | TradingView | AbbVie Q1 Earnings Loom: Buy or Sell the Stock Ahead of Results? - TradingView |
| 2026-04-23 | -1.3% | legal | Stock Titan | AbbVie’s aesthetic neurotoxin faces FDA manufacturing questions - Stock Titan |
| 2026-04-23 | -1.3% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | ABBV (AbbVie Inc.) posts narrow Q4 2025 EPS beat, shares dip slightly in daily trading. - Hot Momentum Watchlist - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2022-11-29 | -1.2% | legal | SEC EDGAR | ABBV 8-K: 5.02 (SEC Filing) |
| 2026-01-26 | +1.2% | news | Yahoo Finance | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance |
| 2026-02-04 | -1.2% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2026-02-04 | -1.2% | earnings | ChartMill | AbbVie Inc. (NYSE:ABBV) Raises 2026 Outlook Despite Q4 Revenue Miss - ChartMill |
| 2026-02-04 | -1.2% | earnings | The Globe and Mail | AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View - The Globe and Mail |
| 2025-02-14 | +1.2% | legal | SEC EDGAR | ABBV 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-03-22 | -1.1% | news | TIKR.com | AbbVie Stock: Here’s Why Street Sets a $249 Mean Target - TIKR.com |
| 2026-04-13 | -1.1% | M&A | Seeking Alpha | AbbVie signs pain drug licensing deal with Chinas Haisco |
| 2026-04-13 | -1.1% | news | DirectorsTalk Interviews | AbbVie Inc. (ABBV) Stock Analysis: A Deep Dive Into A Promising 19.76% Potential Upside - DirectorsTalk Interviews |
| 2026-04-14 | -1.1% | earnings | MarketBeat | Natural Investments LLC Decreases Stake in AbbVie Inc. $ABBV - MarketBeat |
| 2025-10-10 | +1.0% | news | Yahoo Finance | Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? - Yahoo Finance |
| 2023-04-05 | +1.0% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2023-03-28 | -0.9% | legal | SEC EDGAR | ABBV 8-K: 1.01, 2.03 (SEC Filing) |
| 2026-03-11 | +0.9% | earnings | Seeking Alpha | AbbVies Skyrizi beaten by UCBs Bimzelx in psoriatic arthritis |
| 2026-03-01 | +0.9% | news | Yahoo Finance | Is AbbVie Inc. (ABBV) One of the Best Cancer Stocks to Invest In Now? - Yahoo Finance |
| 2026-02-28 | +0.9% | analyst | Seeking Alpha | Notable analyst calls this week: Alphabet, Comcast and IBM among top picks |
| 2026-01-16 | +0.9% | news | Yahoo Finance | AbbVie Inc.'s (NYSE:ABBV) institutional investors lost 3.3% last week but have benefitted from longer-term gains - Yahoo Finance |
| 2024-02-20 | -0.9% | legal | SEC EDGAR | ABBV 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-02-05 | +0.8% | legal | SEC EDGAR | ABBV 8-K: 8.01 (SEC Filing) |
| 2022-10-14 | +0.8% | legal | SEC EDGAR | ABBV 8-K: 5.02, 5.03 (SEC Filing) |
| 2026-03-04 | -0.8% | news | Seeking Alpha | AbbVie: Stabilizes Near $233 While Testing Resistance |
| 2026-03-04 | -0.8% | news | Seeking Alpha | AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript |
| 2026-03-04 | -0.8% | legal | SEC EDGAR | ABBV 8-K: 8.01 and (SEC Filing) |
| 2026-02-10 | -0.8% | news | TIKR.com | Is AbbVie Stock Overvalued in 2026 After a 15% Rally Last Year? - TIKR.com |
| 2026-04-20 | -0.7% | news | Yahoo Finance | AbbVie (ABBV) Is One Of The Major Stock To Buy According To Wall Street - Yahoo Finance |
| 2026-04-20 | -0.7% | earnings | MarketBeat | AbbVie Inc. $ABBV Holdings Cut by Miller Howard Investments Inc. NY - MarketBeat |
| 2026-04-20 | -0.7% | news | DirectorsTalk Interviews | AbbVie Inc. (ABBV) Stock Analysis: An In-Depth Look At Its 19.49% Upside Potential - DirectorsTalk Interviews |
| 2024-02-26 | +0.7% | legal | SEC EDGAR | ABBV 8-K: 8.01 and (SEC Filing) |
| 2023-10-04 | -0.7% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2023-07-06 | -0.5% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2025-12-10 | -0.5% | analyst | Yahoo Finance | HSBC Upgrades AbbVie (ABBV) to Buy, Raises Price Target to $265 - Yahoo Finance |
| 2026-01-07 | +0.4% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2026-01-07 | +0.4% | news | Yahoo Finance | AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73 - Yahoo Finance |
| 2026-03-10 | +0.4% | news | Seeking Alpha | AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript |
| 2026-03-19 | +0.4% | news | Trefis | What’s Happening With AbbVie Stock? - Trefis |
| 2026-03-19 | +0.4% | news | Forbes | Buy Or Fear AbbVie Stock At $210? - Forbes |
| 2025-01-06 | -0.4% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2021-08-19 | +0.4% | legal | SEC EDGAR | ABBV 8-K: 8.01 (SEC Filing) |
| 2025-08-18 | +0.3% | news | Yahoo Finance | Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock - Yahoo Finance |
| 2024-07-03 | -0.2% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2026-04-07 | -0.2% | news | Seeking Alpha | TrumpRx adds medicines from AbbVie and Roches Genentech: report |
| 2026-04-07 | -0.2% | news | The Motley Fool | Should You Buy AbbVie Stock Before April 29? - The Motley Fool |
| 2026-04-07 | -0.2% | earnings | Seeking Alpha | AbbVie: Lowered Guidance Is Just Noise - Reiterate Buy - Seeking Alpha |
| 2026-01-21 | +0.2% | news | Yahoo Finance | AbbVie (ABBV) Looks to Deepen Its Push Into Rapidly Growing Obesity-Treatment Market - Yahoo Finance |
| 2026-04-08 | -0.2% | news | Seeking Alpha | AbbVie: Upside Potential And Dividends With Competent Portfolio Renewal |
| 2026-04-08 | -0.2% | earnings | Seeking Alpha | AbbVie: Lowered Guidance Is Just Noise - Reiterate Buy |
| 2026-04-08 | -0.2% | news | Yahoo Finance | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance |
| 2026-04-08 | -0.2% | earnings | MarketBeat | Yousif Capital Management LLC Decreases Stock Holdings in AbbVie Inc. $ABBV - MarketBeat |
| 2026-03-15 | -0.2% | news | Yahoo Finance | Is AbbVie Inc. (ABBV) A Good Stock to Buy Now? - Yahoo Finance |
| 2023-10-12 | +0.2% | legal | SEC EDGAR | ABBV 8-K: 5.02 (SEC Filing) |
| 2026-01-10 | -0.2% | analyst | Yahoo Finance | AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research - Yahoo Finance |
| 2025-12-30 | -0.2% | news | Yahoo Finance | BofA Cuts AbbVie (ABBV) Target While Maintaining Neutral View - Yahoo Finance |
| 2023-06-29 | +0.1% | legal | SEC EDGAR | ABBV 8-K: 5.02 (SEC Filing) |
| 2022-10-05 | +0.1% | legal | SEC EDGAR | ABBV 8-K: 2.02 and (SEC Filing) |
| 2025-12-17 | -0.0% | news | Yahoo Finance | Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? - Yahoo Finance |
| 2025-12-17 | -0.0% | analyst | Yahoo Finance | Analysts Split on AbbVie Inc. (ABBV) as BofA Cuts Target and HSBC Turns Bullish - Yahoo Finance |
| 2025-11-03 | +0.0% | analyst | Yahoo Finance | Analyst on AbbVie (ABBV): ‘Stay Long’ - Yahoo Finance |
| 2025-11-03 | +0.0% | news | Yahoo Finance | Here’s What Drove Baron Health Care Fund to Add AbbVie (ABBV) to Its Portfolio - Yahoo Finance |
| 2026-04-26 | — | earnings | MarketBeat | Axecap Investments LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat |
| 2026-04-26 | — | earnings | MarketBeat | Advisors Capital Management LLC Purchases 20,147 Shares of AbbVie Inc. $ABBV - MarketBeat |
| 2026-04-26 | — | earnings | MarketBeat | AEGON ASSET MANAGEMENT UK Plc Sells 20,049 Shares of AbbVie Inc. $ABBV - MarketBeat |
| 2026-04-25 | — | legal | Benzinga | AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug |
| 2026-04-25 | — | news | 24/7 Wall St. | Healthcare CEF Insiders Are Quietly Buying While 60% of Distributions Return Capital |
| 2026-04-25 | — | earnings | MarketBeat | Calamos Advisors LLC Grows Stock Holdings in AbbVie Inc. $ABBV - MarketBeat |
| 2026-04-25 | — | earnings | MarketBeat | Golden Reserve Retirement LLC Invests $1.68 Million in AbbVie Inc. $ABBV - MarketBeat |
| 2026-04-24 | — | news | Simply Wall St. | 3 Stocks That Might Be Undervalued By Up To 48.3% Offering A Possible Discount |
| 2026-04-24 | — | legal | Zacks | AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues |
| 2026-04-24 | — | earnings | Zacks | Insights Into AbbVie (ABBV) Q1: Wall Street Projections for Key Metrics |
| 2026-04-24 | — | news | Simply Wall St. | LSI Industries And 2 Other Stocks That May Be Priced Below Estimated Value |
| 2026-04-24 | — | news | PR Newswire | 15 Press Releases You Need to See This Week |
| 2026-04-24 | — | legal | Seeking Alpha | AbbVie anti-wrinkle therapy rejected at FDA |
| 2026-04-24 | — | earnings | MarketBeat | AbbVie (NYSE:ABBV) Trading Down 1.1% - Time to Sell? - MarketBeat |
| 2026-04-24 | — | legal | Seeking Alpha | AbbVie anti-wrinkle therapy rejected at FDA (ABBV:NYSE) - Seeking Alpha |